276 related articles for article (PubMed ID: 12386264)
1. Vitamin D analogues for secondary hyperparathyroidism.
Brown AJ; Dusso AS; Slatopolsky E
Nephrol Dial Transplant; 2002; 17 Suppl 10():10-9. PubMed ID: 12386264
[TBL] [Abstract][Full Text] [Related]
2. [Renal failure and vitamin D].
Brown AJ; Dusso AS; Slatopolsky E
Clin Calcium; 2002 Jun; 12(6):711-23. PubMed ID: 15775356
[TBL] [Abstract][Full Text] [Related]
3. Vitamin D analogs: perspectives for treatment.
Brown AJ; Slatopolsky E
Miner Electrolyte Metab; 1999; 25(4-6):337-41. PubMed ID: 10681662
[TBL] [Abstract][Full Text] [Related]
4. 1alpha(OH)D3 One-alpha-hydroxy-cholecalciferol--an active vitamin D analog. Clinical studies on prophylaxis and treatment of secondary hyperparathyroidism in uremic patients on chronic dialysis.
Brandi L
Dan Med Bull; 2008 Nov; 55(4):186-210. PubMed ID: 19232159
[TBL] [Abstract][Full Text] [Related]
5. Vitamin D analogues for the management of secondary hyperparathyroidism.
Martin KJ; González EA
Am J Kidney Dis; 2001 Nov; 38(5 Suppl 5):S34-40. PubMed ID: 11689385
[TBL] [Abstract][Full Text] [Related]
6. Vitamin D analogs: new therapeutic agents for secondary hyperparathyroidism.
Brown AJ; Coyne DW
Treat Endocrinol; 2002; 1(5):313-27. PubMed ID: 15832485
[TBL] [Abstract][Full Text] [Related]
7. Effects of i.v. and oral 1,25-dihydroxy-22-oxavitamin D(3) on secondary hyperparathyroidism in dogs with chronic renal failure.
Takahashi F; Furuichi T; Yorozu K; Kawata S; Kitamura H; Kubodera N; Slatopolsky E
Nephrol Dial Transplant; 2002; 17 Suppl 10():46-52. PubMed ID: 12386269
[TBL] [Abstract][Full Text] [Related]
8. A comparison between 1,25-dihydroxy-22-oxavitamin D(3) and 1,25-dihydroxyvitamin D(3) regarding suppression of parathyroid hormone secretion and calcaemic action.
Hirata M; Endo K; Katsumata K; Ichikawa F; Kubodera N; Fukagawa M
Nephrol Dial Transplant; 2002; 17 Suppl 10():41-5. PubMed ID: 12386268
[TBL] [Abstract][Full Text] [Related]
9. New Vitamin D analogues for osteodystrophy in chronic kidney disease.
Cunningham J
Pediatr Nephrol; 2004 Jul; 19(7):705-8. PubMed ID: 15141342
[TBL] [Abstract][Full Text] [Related]
10. Use and indication of vitamin D and vitamin D analogues in patients with renal bone disease.
Malluche HH; Monier-Faugere MC; Koszewski NJ
Nephrol Dial Transplant; 2002; 17 Suppl 10():6-9. PubMed ID: 12386263
[TBL] [Abstract][Full Text] [Related]
11. New vitamin D analogs.
Slatopolsky E; Finch J; Brown A
Kidney Int Suppl; 2003 Jun; (85):S83-7. PubMed ID: 12753273
[TBL] [Abstract][Full Text] [Related]
12. A comparison between daily and thrice-weekly i.v. administration of 1,25-dihydroxy-22-oxavitamin D(3) regarding suppression of parathyroid hormone secretion and calcaemic action in uraemic rats.
Hirata M; Endo K; Ohkawa H; Kumaki K; Kubodera N; Slatopolsky E; Kurokawa K; Fukagawa M
Nephrol Dial Transplant; 2002; 17 Suppl 10():37-40. PubMed ID: 12386267
[TBL] [Abstract][Full Text] [Related]
13. Effects of new vitamin D analogues on parathyroid function in chronically uraemic rats with secondary hyperparathyroidism.
Hruby M; Ureña P; Mannstadt M; Schmitt F; Lacour B; Drüeke TB
Nephrol Dial Transplant; 1996 Sep; 11(9):1781-6. PubMed ID: 8918622
[TBL] [Abstract][Full Text] [Related]
14. Effects of 1,25-dihydroxy-22-oxavitamin D(3) on parathyroid gland function in haemodialysis patients with secondary hyperparathyroidism.
Kinugasa E; Akizawa T; Takahashi J; Nabeshima K; Ogata H; Nakayama F; Ideura T
Nephrol Dial Transplant; 2002; 17 Suppl 10():20-7. PubMed ID: 12386265
[TBL] [Abstract][Full Text] [Related]
15. Medical management of secondary hyperparathyroidism in chronic renal failure.
Goodman WG
Nephrol Dial Transplant; 2003 Jun; 18 Suppl 3():iii2-8. PubMed ID: 12771290
[TBL] [Abstract][Full Text] [Related]
16. Vitamin D analogs for secondary hyperparathyroidism: what does the future hold?
Brown AJ
J Steroid Biochem Mol Biol; 2007 Mar; 103(3-5):578-83. PubMed ID: 17368185
[TBL] [Abstract][Full Text] [Related]
17. Vitamin D retains an important role in the pathogenesis and management of secondary hyperparathyroidism in chronic renal failure.
Cozzolino M; Gallieni M; Brancaccio D; Arcidiacono T; Bianchi G; Vezzoli G
J Nephrol; 2006; 19(5):566-77. PubMed ID: 17136683
[TBL] [Abstract][Full Text] [Related]
18. Long-term effect of 1,25-dihydroxy-22-oxavitamin D(3) on secondary hyperparathyroidism in haemodialysis patients. One-year administration study.
Akizawa T; Suzuki M; Akiba T; Nishizawa Y; Ohashi Y; Ogata E; Slatopolsky E; Kurokawa K
Nephrol Dial Transplant; 2002; 17 Suppl 10():28-36. PubMed ID: 12386266
[TBL] [Abstract][Full Text] [Related]
19. Effect of 22-oxacalcitriol on hyperparathyroidism of dialysis patients: results of a preliminary study.
Kurokawa K; Akizawa T; Suzuki M; Akiba T; Ogata E; Slatopolsky E
Nephrol Dial Transplant; 1996; 11 Suppl 3():121-4. PubMed ID: 8840326
[TBL] [Abstract][Full Text] [Related]
20. Drug insight: vitamin D analogs in the treatment of secondary hyperparathyroidism in patients with chronic kidney disease.
Brown AJ; Slatopolsky E
Nat Clin Pract Endocrinol Metab; 2007 Feb; 3(2):134-44. PubMed ID: 17237840
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
